Lymphoplasmacytic lymphoma or Plasmacytoma of the Ovary? A case report and a literature Review

Tiziana Tomaselli 1, Drusilla Rollo 1, Francesco Tarsitano 1, Rosangela Trezzi 2, Claudio Crescini 1

1 Department of Gynecology and Obstetrics, ASST Bergamo Ovest, Treviglio, Italy.
2 Department of Pathology, ASST Papa Giovanni XXIII, Bergamo, Italy.

ABSTRACT
Extramedullary plasmacytoma (EMP) are rare neoplasms, most commonly occurring in the upper respiratory tract and rarely arise in the ovary. Review of the literature reveals nine previously reported cases of ovarian plasmacytomas. Lymphoplasmacytic lymphoma is an indolent B cell lymphoma commonly with bone marrow and lymphnode involvement. Extranodal involvement is rare, and in the ovary extremely rare 1. Unfortunately, there has been no consistent immunologic evaluation of such specimens nor has systematic workup or follow-up been discussed.

Keywords: extramedullary plasmacytoma, neoplasms, lymphoplasmacytic.

INTRODUCTION
Extramedullary plasmacytoma (EMP) are rare neoplasms, most commonly occurring in the upper respiratory tract and rarely arise in the ovary. Review of the literature reveals nine previously reported cases of ovarian plasmacytomas.

Lymphoplasmacytic lymphoma is an indolent B cell lymphoma commonly with bone marrow and lymphnode involvement. Extranodal involvement is rare, and in the ovary extremely rare 1. Unfortunately, there has been no consistent immunologic evaluation of such specimens nor has systematic workup or follow-up been discussed.

CASE REPORT
A 46-year-old woman presented with a history of abdominal mass associated with acute episodes of pain.

On vaginal and rectal examination, the uterus and cervix felt normal. A mobile abdomino-pelvic mass measuring 13.6 x 8.8 cm arising from the right adnexa. There was tenderness during examination. Bilateral parametria were supple and rectal mucosa was free. Except for a haemoglobin level of 10.3 g/dl, the remainder of the haemogram, serum biochemistry, chest X-ray, serum anti-HbsAg and HCV levels were normal. Serum cancer antigen Ca125: 25.2 U/ml; Ca15.3: 35.8 U/ml; Ca19.9: 6.1 U/ml, CEA: 0.4 ng/ml. An ultrasound revealed the presence of heterogeneous mass measuring 13.6x8.8 cm with...
multiple septa. A CT scan of the abdomen showed a large pelvic mass measuring 12x12x14 cm arising from the right adnexa with a solid area measuring 8 cm. No ascites and others localitations.

The patient subsequently underwent an exploratory laparotomy. During surgery a complete adhesiolysis of pelvic adhesion was made. A very vascular right ovarian mass measuring 15x14x10 cm, with solid cystic areas adherent to the uterus and the sigma rectum, was seen. The cervix, appendix, omentum, and upper abdominal viscerae were normal. Left tube and ovary and right tube were removed previously. Bulky nodes were not palpable along the paraaortic and iliac regions. An intraoperative frozen section revealed the presence of poorly differentiated neoplasm carcinoma. An extrafascial hysterectomy with oophorectomy was performed. No residual tumor. Blood loss was 900 ml. She was submitted to blood transfusion and was discharged on the eighth post-operative day. Post-operative PET was negative, conversely CT scan showed millimetric peritoneal nodules. The patient was referred to the haematological oncology service and was evaluated by the multiple myeloma program to stage her plasma cell dyscrasia (complete blood count, serum protein electrophoresis, serum immunofixation, urine immunofixation and urine protein electrophoresis). She also underwent a bone marrow aspirate and biopsy with 10% plasma cells. In view of the limited anatomical disease in our case, the patient is receiving follow-up care and there wasn’t any evidence of recurrence clinically in the last 16 months. Medical scans in the follow up included a CT chest, abdomen and pelvis and abdominal ultrasound. The Adjuvant treatment is not clearly established; however, if complete surgical resection is achieved and no evidence of multiple myeloma is found, observation should be strongly considered.

PATHOLOGY

The histological examination reveal a diffuse ovarian infiltrate composed by clonal well differentiated plasmacells. The neoplastic population was CD138 positive and CD20 negative, with clonal expression of Lambda light chain (Figure 1).

It requested a second opinion on slides reading.

**DISCUSSION**

EMP is a rare primary soft tissue plasma cell tumor. These tumors are known to originate in a variety of anatomical sites, although more than 90% have been reported as developing in the head or neck area, and most of these arise in the upper respiratory passages. EMP constitute fewer than 5% of all plasma cell tumors, generally remain localized, and are more responsive to therapy. Voegt initially reported a case of ovarian plasmacytoma in 1938; he described the tumor as the size of a fist. Since that time, eight other cases, have been reported (Table 1). Review of the reported cases reveals inconsistent evaluations; review of the literature reveals that in the early years the principal form of treatment of EMP was surgery for accessible lesions. However, the current treatment of choice is radiotherapy for localized disease. The median survival of patients with EMP is reported to vary from 4-10 years. Only one experience exists regarding adjuvant postsurgical therapy for patient with extramedullary plasmacytoma of the ovary. Shakuntala et al. reported a patient start three cycles of single agent carboplatin for rapidly refilling ascites and pleural effusion.

In summary, extramedullary plasmacytomas is an exceedingly uncommon tumor, especially with solitary involvement of the ovary. We report the nine such case ever identified in the literature. These tumors are usually large at the time of presentation, more likely involving the left ovary and usually without evidence of disseminated disease. Adjuvant treatment for ovarian plasmacytomas is not clearly established; however, if complete surgical resection is achieved and no evidence of multiple myeloma is found, observation should be strongly considered.

A clonal plasma cell proliferation can be the expression of a plasmacitoma or a lymphoplasmocytic lymphoma with an extreme plasma cells differentiation.
This case propose the differential diagnoses between this two entities. Although the CD20 negativity the patient has also a nodal envolvement so the clinical data suggested the final diagnosis of B lymphoma.

Primary lymphoma of ovary is rare and can be of Burkitt’s, T or B cell types.

Lymphomas secondarily involving ovary are seen in up to 25% of advanced cases. Majority of cases will have concomitant lymphadenopathy. Grossly, the ovarian surface is smooth and parenchymal involvement can be partial or complete. Bi-laterality is encountered in 60% of cases. Burkitt, diffuse large B cell, follicular lymphoma, plasmacytoma, Hodgkin lymphoma and many others were reported (20) (Table 1).

Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images.

The author(s) declare that they have no competing interests. All authors deny any financial and personal relationships with other people or organizations that could inappropriately influence their work and affirm that the manuscript has not been published previously and is not being considered concurrently by another publication.

Table 1.
Clinical characteristics, pathologic variables, Ca125 and outcome for the nine reported cases of ovarian plasmacytoma.

<table>
<thead>
<tr>
<th>Author</th>
<th>Age/symptoms</th>
<th>Ovarian size/side</th>
<th>Ig</th>
<th>Ca125 and LDH</th>
<th>Postsur. CT</th>
<th>FUP</th>
<th>FUP status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veeg1 1938</td>
<td>30/ no symptoms</td>
<td>“viz”</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Bambirra 1984</td>
<td>44/ abd. pain</td>
<td>Right: 14.3x5.3xcm Left: 12.3x9.3xcm</td>
<td>IgG</td>
<td>NA</td>
<td>NA</td>
<td>3 months</td>
<td>DOD</td>
</tr>
<tr>
<td>Haustzer 1984</td>
<td>56/ abd. mass</td>
<td>Left: 26x30x14.3cm</td>
<td>IgG</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Taelerman 1987</td>
<td>35/ abd. mass</td>
<td>Unilateral: 15.3x12.3x9cm</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>9 months</td>
<td>NA</td>
</tr>
<tr>
<td>CooK 1988</td>
<td>63/ abd. mass</td>
<td>Left: 12.3x10x3.7cm</td>
<td>IgA</td>
<td>NA</td>
<td>NA</td>
<td>24 months</td>
<td>NA</td>
</tr>
<tr>
<td>Andze 1993</td>
<td>12/ pelv. mass</td>
<td>Left: 12.3x8x3.8cm</td>
<td>Negative</td>
<td>NA</td>
<td>NA</td>
<td>11 months</td>
<td>NA</td>
</tr>
<tr>
<td>Emery JD 1999</td>
<td>54/ abd. swell</td>
<td>Left: 15.3x13x3.8cm</td>
<td>IgG</td>
<td>NA</td>
<td>NA</td>
<td>24+months</td>
<td>NED</td>
</tr>
<tr>
<td>Zhong YP 2012</td>
<td>54/ abd. pain</td>
<td>Right: 12x12x10cm</td>
<td>MM IgA-type stage A</td>
<td>NA</td>
<td>Proposed bortezomib and dexamethasone, etoposide, cyclophosphamide and cisplatin</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Shakantala 2012</td>
<td>35/ abd. mass</td>
<td>Right: 14x13.5x6cm</td>
<td>Not done</td>
<td>178 and 899</td>
<td>Weekly carboplatin AUC2</td>
<td>Postsurgical Ca125: 17.7U/ml</td>
<td>14 months</td>
</tr>
</tbody>
</table>
REFERENCES